Get Adobe Flash player


Improving current EU policies and regulations


Policymakers require scientific results to underpin their environmental policy. Demand for science-based policy is especially high in human health and environmental policies, where it is critical to ensure the best possible understanding of potential risks and ways to minimize them.


PHARMAS will improve the understanding on pharmaceutical products in the aquatic environment, thereby providing information that could address policy gaps or guide policy initiatives. The data collected and the new data generated (eg. knowledge on the fate and effects of PPs in the environment, knowledge on low-level effects and chronic effects of PPs, cumulative effects of multiple PP substances) will be easily available and accessible.


In addition, Pharmas will contribute to an evolution of the regulation and EU policies by distilling the policy-relevant information out of research products, and provide project conclusions for the relevant policy fields. Policy makers can look to PHARMAS for identifying existing gaps in regulations and policies and identify the opportunities to reduce health risks related to the use of pharmaceuticals.


PHARMAS will generate new knowledge in fields that are directly related to current regulations, such as the environmental risk assessment of pharmaceutical products, as well as generating new knowledge for areas in which current knowledge is poor, such as mixture toxicity.


Stay connected to Pharmas


The policy-linked outcomes will be published in journals generally accessible to decision makers, administrators, and managers (e.g., Science for Environment Policy Newsletter, Environment Science and Policy, Health Policy, Food Policy, etc.).


A Policy Brief will be produced and disseminated, which will distil the policy-relevant information, products and conclusions of the project for the relevant policy fields. This brief will “translate” the academic results for decision-/policy-makers, administrators, and managers.


Finally, the results of PHARMAS will be presented and discussed in relevant policy meetings and workshops organised by key organizations.